{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:52Z","timestamp":1790803612018,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Parts of this study was funded by the Ministry of Science, Research and Arts Baden W\u00fcrttemberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Leptomeningeal metastatic disease (LMD) of solid tumors represents a cancer stage with high unmet therapeutic need. Here we report results from the dose escalation part of a multicenter phase 1 trial investigating intraventricular nivolumab, now continuing in the expansion part. Eligible participants had LMD from tumors with an approval for intraveneous PD1\/PDL1 therapy or high tumor mutational burden. The primary endpoint was safety across four dose levels (20, 30, 40 and 50\u2009mg) with each cohort reviewed by an independent data safety monitoring board before escalation. The secondary endpoint was overall survival. Exploratory endpoints included participant-reported outcome measures. Of 30 enrolled participants, 24 received at least one dose (intention-to-treat population) and 18 completed predefined safety evaluations (per-protocol population). One dose-limiting toxicity occurred at 40\u2009mg. The primary endpoint was met and the recommended fixed dose for the ongoing expansion part is 50\u2009mg. Median overall survival (OS) was 6.6\u2009months. The 6-month, 12-month and 18-month OS rates were 55.0% (95% confidence interval (CI): 37.5\u201380.6%), 33.3% (95% CI: 17.8\u201362.4%) and 16.7% (95% CI 6.03\u201346.1%), respectively. Participant-reported quality of life remained stable. Intraventricular nivolumab has demonstrated safety and feasibility (ClinicalTrials.gov:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05112549\" ext-link-type=\"uri\">NCT05112549<\/jats:ext-link>\n                    ).\n                  <\/jats:p>","DOI":"10.1038\/s43018-026-01185-4","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:03:33Z","timestamp":1780563813000},"page":"1094-1103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1\/NOA-26 phase 1 trial"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-8782","authenticated-orcid":false,"given":"Ghazaleh","family":"Tabatabai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2477-664X","authenticated-orcid":false,"given":"Isabel","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Bombach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"Mayer-Steinacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4340-9706","authenticated-orcid":false,"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0299-1138","authenticated-orcid":false,"given":"Nicolas","family":"Neidert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Roelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8825-4908","authenticated-orcid":false,"given":"Iris","family":"Mildenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-7574","authenticated-orcid":false,"given":"Lukas","family":"Bunse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-887X","authenticated-orcid":false,"given":"Michael","family":"Platten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-9327","authenticated-orcid":false,"given":"Ulrich","family":"Herrlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-4359","authenticated-orcid":false,"given":"Uwe M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Ernemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Tatagiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5182-8295","authenticated-orcid":false,"given":"Lina Maria","family":"Serna-Higuita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5386-5732","authenticated-orcid":false,"given":"Peter","family":"Martus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Renovanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"1185_CR1","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","volume":"23","author":"N Lamba","year":"2021","unstructured":"Lamba, N., Wen, P. Y. & Aizer, A. A. Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol. 23, 1447\u20131456 (2021).","journal-title":"Neuro Oncol."},{"key":"1185_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/neuonc\/noac249","volume":"25","author":"N Lamba","year":"2023","unstructured":"Lamba, N. et al. Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. Neuro Oncol. 25, 973\u2013983 (2023).","journal-title":"Neuro Oncol."},{"key":"1185_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-025-01412-y","volume":"25","author":"U Sener","year":"2025","unstructured":"Sener, U., Wilcox, J. A. & Boire, A. A. Leptomeningeal disease: current approaches and future directions. Curr. Neurol. Neurosci. Rep. 25, 25 (2025).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"1185_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28662-w","volume":"8","author":"Z Pan","year":"2018","unstructured":"Pan, Z. et al. Leptomeningeal metastasis from solid tumors: clinical features and its diagnostic implication. Sci. Rep. 8, 10445 (2018).","journal-title":"Sci. Rep."},{"key":"1185_CR5","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/neuonc\/noaa298","volume":"23","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun, E. et al. Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro Oncol. 23, 1100\u20131112 (2021).","journal-title":"Neuro Oncol."},{"key":"1185_CR6","doi-asserted-by":"publisher","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","volume":"28","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun, E. et al. EANO\u2013ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann. Oncol. 28, iv84\u2013iv99 (2017).","journal-title":"Ann. Oncol."},{"key":"1185_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101624","volume":"8","author":"E Le Rhun","year":"2023","unstructured":"Le Rhun, E. et al. Leptomeningeal metastasis from solid tumours: EANO\u2013ESMO clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open 8, 101624 (2023).","journal-title":"ESMO Open"},{"key":"1185_CR8","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/neuonc\/noac043","volume":"24","author":"E Le Rhun","year":"2022","unstructured":"Le Rhun, E. et al. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort. Neuro Oncol. 24, 1726\u20131735 (2022).","journal-title":"Neuro Oncol."},{"key":"1185_CR9","doi-asserted-by":"publisher","DOI":"10.2217\/cns-2018-0007","volume":"8","author":"UN Chukwueke","year":"2019","unstructured":"Chukwueke, U. N. & Wen, P. Y. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. 8, CNS28 (2019).","journal-title":"CNS Oncol."},{"key":"1185_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/neuonc\/noz012","volume":"21","author":"A Boire","year":"2019","unstructured":"Boire, A. et al. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol. 21, 571\u2013584 (2019).","journal-title":"Neuro Oncol."},{"key":"1185_CR11","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1007\/s13311-022-01261-4","volume":"19","author":"JA Wilcox","year":"2022","unstructured":"Wilcox, J. A., Li, M. J. & Boire, A. A. Leptomeningeal metastases: new opportunities in the modern era. Neurotherapeutics 19, 1782\u20131798 (2022).","journal-title":"Neurotherapeutics"},{"key":"1185_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01224","volume":"9","author":"SM Buszek","year":"2019","unstructured":"Buszek, S. M. & Chung, C. Radiotherapy in leptomeningeal disease: a systematic review of randomized and non-randomized trials. Front. Oncol. 9, 1224 (2019).","journal-title":"Front. Oncol."},{"key":"1185_CR13","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.22.01148","volume":"40","author":"JT Yang","year":"2022","unstructured":"Yang, J. T. et al. Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis. J. Clin. Oncol. 40, 3858\u20133867 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1185_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/neuonc\/noz201","volume":"22","author":"E Le Rhun","year":"2020","unstructured":"Le Rhun, E. et al. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Neuro Oncol. 22, 524\u2013538 (2020).","journal-title":"Neuro Oncol."},{"key":"1185_CR15","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1016\/j.cllc.2022.11.011","volume":"24","author":"H Li","year":"2023","unstructured":"Li, H. et al. Safety, pharmacokinetic and clinical activity of intrathecal chemotherapy with pemetrexed via the Ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: a prospective phase I study. Clin. Lung Cancer 24, e94\u2013e104 (2023).","journal-title":"Clin. Lung Cancer"},{"key":"1185_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00838","volume":"9","author":"Z Pan","year":"2019","unstructured":"Pan, Z. et al. A pilot phase 1 study of intrathecal pemetrexed for refractory leptomeningeal metastases from non-small-cell lung cancer. Front. Oncol. 9, 838 (2019).","journal-title":"Front. Oncol."},{"key":"1185_CR17","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1038\/s41591-025-03744-1","volume":"31","author":"M Preusser","year":"2025","unstructured":"Preusser, M. et al. Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial. Nat. Med. 31, 2797\u20132805 (2025).","journal-title":"Nat. Med."},{"key":"1185_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noac195","volume":"25","author":"PU Kumthekar","year":"2023","unstructured":"Kumthekar, P. U. et al. A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro Oncol. 25, 557\u2013565 (2023).","journal-title":"Neuro Oncol."},{"key":"1185_CR19","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","volume":"26","author":"PK Brastianos","year":"2020","unstructured":"Brastianos, P. K. et al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat. Med. 26, 1280\u20131284 (2020).","journal-title":"Nat. Med."},{"key":"1185_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25860-5","volume":"12","author":"SM Prakadan","year":"2021","unstructured":"Prakadan, S. M. et al. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nat. Commun. 12, 5955 (2021).","journal-title":"Nat. Commun."},{"key":"1185_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002473","volume":"9","author":"J Naidoo","year":"2021","unstructured":"Naidoo, J. et al. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. J Immunother. Cancer 9, e002473 (2021).","journal-title":"J Immunother. Cancer"},{"key":"1185_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25859-y","volume":"12","author":"PK Brastianos","year":"2021","unstructured":"Brastianos, P. K. et al. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat. Commun. 12, 5954 (2021).","journal-title":"Nat. Commun."},{"key":"1185_CR23","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","volume":"29","author":"IC Glitza Oliva","year":"2023","unstructured":"Glitza Oliva, I. C. et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat. Med. 29, 898\u2013905 (2023).","journal-title":"Nat. Med."},{"key":"1185_CR24","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","volume":"168","author":"A Boire","year":"2017","unstructured":"Boire, A. et al. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 168, 1101\u20131113 (2017).","journal-title":"Cell"},{"key":"1185_CR25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1126\/science.aaz2193","volume":"369","author":"Y Chi","year":"2020","unstructured":"Chi, Y. et al. Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. Science 369, 276\u2013282 (2020).","journal-title":"Science"},{"key":"1185_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4047617","volume":"2019","author":"DM Byrnes","year":"2019","unstructured":"Byrnes, D. M. et al. Complications of intrathecal chemotherapy in adults: single-institution experience in 109 consecutive patients. J. Oncol. 2019, 4047617 (2019).","journal-title":"J. Oncol."},{"key":"1185_CR27","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045(10)70034-6","volume":"11","author":"P Beauchesne","year":"2010","unstructured":"Beauchesne, P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 11, 871\u2013879 (2010).","journal-title":"Lancet Oncol."},{"key":"1185_CR28","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/jjco\/hyg118","volume":"33","author":"DY Kim","year":"2003","unstructured":"Kim, D. Y. et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn. J. Clin. Oncol. 33, 608\u2013612 (2003).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"1185_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000283","volume":"3","author":"IC Glitza","year":"2018","unstructured":"Glitza, I. C. et al. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3, e000283 (2018).","journal-title":"ESMO Open"},{"key":"1185_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092508","volume":"15","author":"OG Trifanescu","year":"2023","unstructured":"Trifanescu, O. G. et al. Therapies beyond physiological barriers and drug resistance: a pilot study and review of the literature investigating if intrathecal trastuzumab and new treatment options can improve oncologic outcomes in leptomeningeal metastases from HER2-positive breast cancer. Cancers (Basel) 15, 2508 (2023).","journal-title":"Cancers (Basel)"},{"key":"1185_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.breast.2023.04.008","volume":"69","author":"AM Lazaratos","year":"2023","unstructured":"Lazaratos, A. M. et al. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. Breast 69, 451\u2013468 (2023).","journal-title":"Breast"},{"key":"1185_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).","journal-title":"Nat. Commun."},{"key":"1185_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40263-022-00975-5","volume":"37","author":"JA Wilcox","year":"2023","unstructured":"Wilcox, J. A. & Boire, A. A. Leveraging molecular and immune-based therapies in leptomeningeal metastases. CNS Drugs 37, 45\u201367 (2023).","journal-title":"CNS Drugs"},{"key":"1185_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2019.05.019","volume":"116","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks, L. E. L. et al. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. Eur. J. Cancer 116, 182\u2013189 (2019).","journal-title":"Eur. J. Cancer"},{"key":"1185_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v094.i13","volume":"94","author":"F Yan","year":"2020","unstructured":"Yan, F., Zhang, L., Zhou, Y., Pan, H., Liu, S. & Yuan, Y. BOIN: an R package for designing single-agent and drug-combination dose-finding trials using Bayesian optimal interval designs. J. Stat. Softw. 94, 1\u201332 (2020).","journal-title":"J. Stat. Softw."},{"key":"1185_CR36","first-page":"e60","volume":"4","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F., Altman, D. G., Moher, D. & Group, C. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Open Med. 4, e60\u2013e68 (2010).","journal-title":"Open Med."},{"key":"1185_CR37","unstructured":"R Core Team R: A Language and Environment for Statistical Computing (R Core Team, 2021)."},{"key":"1185_CR38","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau, C., Lee, J. J. & Siu, L. L. Dose escalation methods in phase I cancer clinical trials. J. Natl Cancer Inst. 101, 708\u2013720 (2009).","journal-title":"J. Natl Cancer Inst."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01185-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01185-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01185-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:01:40Z","timestamp":1784901700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01185-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01185-4","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional funding to the University Hospital T\u00fcbingen was provided as financial compensation for the following activities of G.T.: advisory boards (Bayer, Boehringer Ingelheim, CureVac, Miltenyi Biomedicine, Novocure and Servier), consultancy (Bayer, Boehringer Ingelheim and CureVac), steering committee member in noninterventional trials (Bayer and Novocure) and lectures (Novocure and Servier). M.P. is the inventor and patent holder on \u2018peptides for use in treating or diagnosing\n                      IDH1\n                      R132H\n                      -positive cancers\u2019 (EP2800580B1). M.P. is founder of Tcelltech. U.H. has received speaker and\/or advisory board honorary from Bayer, Medac, Servier and OncomagnetX. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}